Search of: HIV Infections - List Results

Home


	List Results


	Refine Search


	Results by Topic


	Results on Map


	Search Details

Found 3089 studies with search of:

HIV Infections

Hide studies that are not seeking new volunteers.

Display Options

1	Completed	A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
		Conditions:	HIV Infections; HIV Seronegativity
		Interventions:	Biological: Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203); Biological: Aluminum hydroxide; Biological: MF59; Biological: rgp120/HIV-1MN

2	Active, not recruiting	Yoga for the Management of HIV-Metabolic Syndromes
		Conditions:	HIV Infections; HIV Metabolic Cardiovascular Syndrome; HIV Lipodystrophy; HIV Metabolic Syndromes
		Interventions:	Behavioral: Yoga lifestyle intervention; Other: Standard of care

3	Completed	Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers
		Conditions:	HIV Infections; HIV Seronegativity
		Intervention:	Biological: APL 400-003

4	Completed	A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
		Conditions:	HIV Infections; HIV Seronegativity
		Interventions:	Biological: gp160 MN/LAI-2; Biological: ALVAC-HIV MN120TMG (vCP205)

5	Active, not recruiting	HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults
		Conditions:	HIV Infections; HIV Seronegativity
		Intervention:	Biological: ALVAC-HIV MN120TMG (vCP205)

6	Active, not recruiting	Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir
		Conditions:	HIV Infections; Human Immunodeficiency Virus; Acquired Immunodeficiency Syndrome Virus; AIDS Virus
		Intervention:	Drug: darunavir

7	Terminated	Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
		Conditions:	HIV Infections; HIV Seronegativity
		Interventions:	Biological: Aluminum hydroxide; Biological: QS-21; Biological: MN rsgp120/HIV-1

8	Active, not recruiting	A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
		Conditions:	HIV Infections; HIV-Associated Lipodystrophy Syndrome; HIV Lipodystrophy Syndrome; Lipodystrophy; Dyslipidemia; Osteoporosis; Osteopenia
		Intervention:

9	Not yet recruiting	PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)
		Conditions:	HIV-Dementia; HIV-Associated Cognitive Motor Complex; AIDS Encephalopathy; AIDS Dementia Complex; AIDS-Related Dementia Complex; HIV Infections; Healthy
		Intervention:	Drug: [11C]PBR28

10	Recruiting	Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
		Conditions:	HIV-1 Infections; HIV Infections
		Interventions:	Drug: Tenofovir Disoproxil Fumarate (TDF); Drug: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF); Drug: Placebo

11	Completed	A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
		Conditions:	HIV Infections; HIV Seronegativity
		Intervention:	Biological: gp160 Vaccine (Immuno-AG)

12	Active, not recruiting	A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers
		Conditions:	HIV Infections; HIV Seronegativity
		Interventions:	Biological: rgp120/HIV-1MN; Biological: rgp120/HIV-1 SF-2; Biological: Placebo version of rgp120/HIV-1MN; Biological: Placebo version of rgp120/HIV-1SF2

13	Completed	Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
		Conditions:	HIV Infections; HIV Seronegativity
		Intervention:	Biological: ALVAC(2)120(B,MN)GNP (vCP1452)

14	Terminated	Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
		Conditions:	HIV Infections; Pregnancy; HIV Seronegativity
		Interventions:	Biological: MF59; Biological: rgp120/HIV-1 SF-2

15	Completed	Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection
		Conditions:	HIV Infections; HIV Seronegativity
		Intervention:	Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1

16	Active, not recruiting	A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers
		Conditions:	HIV Infections; HIV Seronegativity
		Interventions:	Biological: ALVAC(2)120(B,MN)GNP (vCP1452); Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1; Biological: ALVAC-HIV MN120TMG (vCP205)

17	Completed	A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults
		Conditions:	HIV Infections; HIV Seronegativity
		Intervention:	Biological: HIV p24/MF59 Vaccine

18	Completed	A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine
		Conditions:	HIV Infections; HIV Seronegativity
		Intervention:	Biological: ALVAC-HIV MN120TMG (vCP205)

19	Recruiting	TMC278-TiDP6-C209: A Clinical Trial in Treatment naïve HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
		Conditions:	HIV-1; Human Immunodeficiency Virus Type 1; HIV Infections
		Interventions:	Drug: TMC278; Drug: efavirenz

20	Completed	A Study of GENEVAX-HIV, a Possible Vaccine
		Conditions:	HIV Infections; HIV Seronegativity
		Intervention:	Biological: APL 400-003

21	Active, not recruiting	A Study to Test the Safety of Three Experimental HIV Vaccines
		Conditions:	HIV Infections; HIV Seronegativity
		Interventions:	Biological: HIV p24/MF59 Vaccine; Biological: ALVAC-HIV MN120TMG (vCP205); Biological: ALVAC-RG Rabies Glycoprotein (vCP65); Biological: rgp120/HIV-1 SF-2

22	Active, not recruiting	Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults
		Condition:	HIV Infections
		Interventions:	Biological: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT); Biological: rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT); Biological: Empty TBC-FPV; Biological: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT); Biological: rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT); Biological: TBC-MVA and TBC-FPV; Biological: TBC-MVA and TBC-FPV; Biological: TBC-MVA and TBC-FPV

23	Completed	A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss
		Conditions:	HIV Infections; HIV Wasting Syndrome
		Interventions:	Drug: Testosterone enanthate; Drug: Megestrol acetate

24	Completed	Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers
		Conditions:	HIV Infections; HIV Seronegativity
		Intervention:	Biological: Lipopeptides LIPO-4

25	Active, not recruiting	The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children
		Conditions:	HIV Infections; HIV Wasting Syndrome; Lipodystrophy
		Intervention:

26	Recruiting	Phase 1 Safety Study of Two Experimental HIV Vaccines
		Conditions:	AIDS Vaccines; HIV Infections; HIV-1
		Interventions:	Drug: VRC-HIVADV027-00-VP; Drug: VRC-HIVADV038-00-VP

27	Completed	Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection
		Condition:	HIV Infections
		Interventions:	Drug: Indinavir sulfate; Drug: Nelfinavir mesylate; Drug: Lamivudine; Drug: Stavudine

28	Active, not recruiting	Comparison of HIV Clinic-Based Treatment With Buprenorphine Versus Referred Care in Heroin-Dependent Participants
		Conditions:	Opiate Dependence; HIV Seropositivity; HIV Infections
		Interventions:	Behavioral: Clinic-based substance abuse treatment with buprenorphine; Behavioral: Case management and referred substance abuse treatment

29	Active, not recruiting	A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
		Conditions:	HIV Infections; HIV Seronegativity; Herpes Genitalis
		Interventions:	Drug: Acyclovir; Drug: Acyclovir placebo

30	Recruiting	Clinical Trial to Evaluate the Safety and Immunogenicity of a Candidate Prophylactic pHIS-HIV-AE DNA Prime and rFPV-HIV-AE Boost HIV Vaccination Strategy
		Condition:	HIV Infections
		Interventions:	Biological: pHIS-HIV-AE DNA Prime; Biological: rFPV-HIV-AE Booster; Biological: Placebo

31	Completed	Randomized Placebo-Controlled Study of Aerobic Exercise and Resistance Training Plus Megestrol Acetate for HIV-Wasting
		Conditions:	Acquired Immunodeficiency Syndrome; HIV Wasting Syndrome; HIV Infections
		Interventions:	Drug: megestrol; Behavioral: Exercise

32	Recruiting	Reactogenicity and Immunogenicity of Vaginal ZM96gp140
		Conditions:	HIV Infections; Human Immunodeficiency Virus; Acquired Immune Deficiency Syndrome
		Interventions:	Biological: HIV glycoprotein 140 ZM96 (vaccine); Biological: Carbopol 974

33	Active, not recruiting	Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults
		Condition:	HIV Infections
		Interventions:	Biological: VRC-HIVADV014-00-VP; Biological: VRC-HIVDNA016-00-VP

34	Recruiting	Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults
		Condition:	HIV Infections
		Interventions:	Biological: HIV-1 gag DNA; Biological: IL-15 DNA adjuvant; Biological: IL-12 DNA adjuvant

35	Completed	A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults
		Condition:	HIV Infections
		Interventions:	Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1; Biological: QS-21; Biological: rgp120/HIV-1MN

36	Completed	A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)
		Condition:	HIV Infections
		Interventions:	Biological: rgp120/HIV-1IIIB; Biological: rgp120/HIV-1MN

37	Completed	A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
		Condition:	HIV Infections
		Interventions:	Biological: ALVAC-HIV MN120TMGNP (vCP300); Biological: ALVAC-RG Rabies Glycoprotein (vCP65); Biological: rgp120/HIV-1 SF-2

38	Completed	A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
		Condition:	HIV Infections
		Interventions:	Biological: ALVAC-HIV MN120TMG (vCP205); Biological: ALVAC-RG Rabies Glycoprotein (vCP65); Biological: rgp120/HIV-1 SF-2

39	Recruiting	Efficacy of Thrice Weekly Directly Observed Treatment, Short-Course (DOTS) in HIV-Associated Tuberculosis
		Conditions:	HIV Infections; Acquired Immunodeficiency Syndrome; Tuberculosis
		Interventions:	Drug: INH, Rifampicin, Ethambutol and Pyrazinamide; Drug: INH, Rifampicin, Ethambutol and Pyrazinamide

40	Completed	A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules
		Condition:	HIV Infections
		Interventions:	Biological: ALVAC-HIV MN120TMG (vCP205); Biological: ALVAC-RG Rabies Glycoprotein (vCP65); Biological: rgp120/HIV-1 SF-2

41	Terminated	A Study to Test the Safety and Effectiveness of Dexelvucitabine, an Investigational Nucleoside Reverse Transcriptase Inhibitor (NRTI), to Lamivudine, an Approved NRTI, in HIV Treatment-Experienced Patients Who Are Resistant to Protease Inhibitors, NRTIs and Non-NRTIs
		Conditions:	HIV Infections; Human Immunodeficiency Virus
		Intervention:	Drug: Dexelvucitabine

42	Terminated	Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients
		Conditions:	HIV Infections; HIV-Associated Lipodystrophy Syndrome
		Interventions:	Drug: non-nucleoside reverse transcriptase inhibitors; Drug: nucleoside reverse transcriptase inhibitors; Drug: protease inhibitor

43	Completed	A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.
		Condition:	HIV Infections
		Interventions:	Biological: HIV-1 Peptide Vaccine, Microparticulate Monovalent; Biological: HIV-1 Peptide Immunogen, Multivalent

44	Completed	A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
		Condition:	HIV Infections
		Interventions:	Biological: Aluminum hydroxide; Biological: QS-21; Biological: rgp120/HIV-1MN

45	Active, not recruiting	Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon
		Conditions:	HIV-1 and HSV-2 Coinfection; HIV Infections
		Intervention:	Drug: Acyclovir

46	Recruiting	Screening Protocol for HIV Vaccine Studies
		Conditions:	HIV Seronegativity; HIV Infections
		Intervention:

47	Completed	Analysis of Immune Responses to HIV Vaccines
		Conditions:	Acquired Immunodeficiency Syndrome; HIV Infections
		Intervention:

48	Active, not recruiting	ALVAC-HIV vCP1452 Alone and Combined With MN rgp120
		Conditions:	HIV Infections; HIV Seronegativity
		Interventions:	Biological: ALVAC(2)120(B,MN)GNP (vCP1452); Biological: MN rgp120/HIV-1; Biological: ALVAC(2)120(B,MN)GNP (vCP1452) placebo; Biological: MN rgp120/HIV-1 placebo

49	Completed	Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS
		Conditions:	HIV Infections; Fatigue; HIV Positive; AIDS; Healthy Volunteer; HV
		Intervention:

50	Completed	A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers
		Condition:	HIV Infections
		Interventions:	Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1; Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1; Biological: ALVAC-HIV MN120TMG (vCP205); Biological: rgp120/HIV-1 SF-2

Studies Shown (1-50)

Next (51-100)

RSS Feed for studies found by your search that were received in the last 14 days

Download Options